Context-dependent adaption of EpCAM expression in early systemic esophageal cancer

Oncogene

Volumn 33, Issue 41, 2013, Pages 4904-4915

  Driemel, C ^a   Kremling, H ^b   Schumacher, S ^a   Will, D ^b   Wolters, J ^a   Lindenlauf, N ^a   Mack, B ^b   Baldus, S A ^a   Hoya, V ^a   Pietsch, J M ^a   Panagiotidou, P ^a   Raba, K ^a   Vay, C ^a   Vallbohmer, D ^a   Harreus, U ^b   Knoefel, W T ^a   Stoecklein, N H ^a   Gires, O ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Disseminated tumor cells; EpCAM; Esophageal cancers

Indexed keywords

ANTINEOPLASTIC AGENT; EPITHELIAL CELL ADHESION MOLECULE; ESOPHAGUS 3METASTASIS; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CANCER PATIENT; CANCER SURGERY; CELL INVASION; CELL MEMBRANE; CELL MIGRATION; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; DOWN REGULATION; ESOPHAGEAL CANCER CELL LINE; ESOPHAGUS CANCER; ESOPHAGUS METASTASIS; ESOPHAGUS SURGERY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MOUSE; NEOADJUVANT THERAPY; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC DISEASE; TUMOR GROWTH; TUMOR INVASION; XENOTRANSPLANTATION;

EID: 84885532962     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.441     Document Type: Article

References (36)

1. Stoecklein NH, Klein CA.. Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis. Int J Cancer 2010; 126: 589-598.
2. Sleeman J, Steeg PS. Cancer metastasis as a therapeutic target. Eur J Cancer 2010; 46: 1177-1180.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
4. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008; 8: 329-340.
5. Floor SL, Dumont JE, Maenhaut C, Raspe E. Hallmarks of cancer: Of all cancer cells, all the time? Trends Mol Med 2012; 18: 509-515.
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
7. Imrich S, Hachmeister M, Gires O. EpCAM and its potential role in tumor-initiating cells. Cell Adh Migr 2012; 6: 30-38.
8. Patriarca C, Macchi RM, Marschner AK, Mellstedt H. Epithelial cell adhesion molecule expression (CD326) in cancer: A short review. Cancer Treat Rev 2012; 38: 68-75.
9. Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009; 69: 5627-5629.
10. Winter MJ, Cirulli V, Briaire-de Bruijn IH, Litvinov SV. Cadherins are regulated by Ep-CAM via phosphaditylinositol-3 kinase. Mol Cell Biochem 2007; 302: 19-26.
11. Litvinov SV, Balzar M, Winter MJ, Bakker HA, Briaire-de Bruijn IH, Prins F et al. Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 1997; 139: 1337-1348.
12. Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 2004; 23: 5748-5758.
13. Chaves-Perez A, Mack B, Maetzel D, Kremling H, Eggert C, Harreus U et al. EpCAM regulates cell cycle progression via control of cyclin D1 expression. Oncogene 2012; 32: 641-650.
14. Gonzalez B, Denzel S, Mack B, Conrad M, Gires O. EpCAM is involved in maintenance of the murine embryonic stem cell phenotype. Stem Cells 2009; 27: 1782-1791.
15. Ng VY, Ang SN, Chan JX, Choo AB. Characterization of epithelial cell adhesion molecule as a surface marker on undifferentiated human embryonic stem cells. Stem Cells 2009; 28: 29-35.
16. Lu TY, Lu RM, Liao MY, Yu J, Chung CH, Kao CF et al. Epithelial cell adhesion molecule regulation is associated with the maintenance of the undifferentiated phenotype of human embryonic stem cells. J Biol Chem 2010; 285: 8719-8732.
17. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M et al. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009; 11: 162-171.
18. Klein CA, Stoecklein NH. Lessons from an aggressive cancer: evolutionary dynamics in esophageal carcinoma. Cancer Res 2009; 69: 5285-5288.
19. Kasai H, Allen JT, Mason RM, Kamimura T, Zhang Z. TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir Res 2005; 6: 56.
20. van der Gun BT, Melchers LJ, Ruiters MH, De Leij LF, McLaughlin PM, Rots MG. EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 2010; 31: 1913-1921.
21. Went P, Vasei M, Bubendorf L, Terracciano L, Tornillo L, Riede U et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 2006; 94: 128-135.
22. Went PT, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004; 35: 122-128.
23. Stoecklein NH, Siegmund A, Scheunemann P, Luebke AM, Erbersdobler A, Verde PE et al. EpCAM expression in squamous cell carcinoma of the esophagus: A potential therapeutic target and prognostic marker. BMC Cancer 2006; 6: 165.
24. Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer 2007; 96: 417-423.
25. Kimura H, Kato H, Faried A, Sohda M, Nakajima M, Fukai Y et al. Prognostic significance of EpCAM expression in human esophageal cancer. Int J Oncol 2007; 30: 171-179.
26. Songun I, Litvinov SV, van de Velde CJ, Pals ST, Hermans J, van Krieken JH. Loss of Ep-CAM (CO17-1A) expression predicts survival in patients with gastric cancer. Br J Cancer 2005; 92: 1767-1772.
27. Vannier C, Mock K, Brabletz T, Driever W. Zeb1 regulates E-cadherin and Epcam expression to control cell behavior in early zebrafish development. J Biol Chem 2013; 288: 18643-18659.
28. Rao CG, Chianese D, Doyle GV, Miller MC, Russell T, Sanders Jr. RA et al. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol 2005; 27: 49-57.
29. Gorges TM, Tinhofer I, Drosch M, Rose L, Zollner TM, Krahn T et al. Circulating tumour cells escape from EpCAM-based detection due to epithelial-tomesenchymal transition. BMC Cancer 2012; 12: 178.
30. Alix-Panabieres C, Riethdorf S, Pantel K. Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res 2008; 14: 5013-5021.
31. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003; 349: 2241-2252.
32. Bao B, Wang Z, Ali S, Kong D, Banerjee S, Ahmad A et al. Over-expression of FoxM1 leads to epithelial-mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. J Cell Biochem 2011; 112: 2296-2306.
33. Biddle A, Liang X, Gammon L, Fazil B, Harper LJ, Emich H et al. Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res 2011; 71: 5317-5326.
34. Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002; 360: 683-689.
35. Raffel A, Eisenberger CF, Cupisti K, Schott M, Baldus SE, Hoffmann I et al. Increased EpCAM expression in malignant insulinoma: potential clinical implications. Eur J Endocrinol 2010; 162: 391-398.
36. Sato M, Vaughan MB, Girard L, Peyton M, Lee W, Shames DS et al. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res. 2006; 66: 2116-2128.